NCT03503149 Molecular Tumor Board at the Center for Personalized Medicine Tübingen
| NCT ID | NCT03503149 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Advanced Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2018-03-01 |
| Primary Completion | 2028-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2018-03-01 with a primary completion date of 2028-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Molecular Tumor Board at the Center for Personalized Medicine
Eligibility Criteria
Inclusion Criteria: * Given informed consent ("broad consent" of the University Hospital Tübingen) * ≥ 18 years of age * Clinical indication for a referral to Molecular Tumor Board by the treating physician Exclusion Criteria: * The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients
Contact & Investigator
Ghazaleh Tabatabai, Prof
PRINCIPAL INVESTIGATOR
University Hospital Tübingen
Frequently Asked Questions
Who can join the NCT03503149 clinical trial?
This trial is open to participants of all sexes, studying Advanced Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03503149 currently recruiting?
Yes, NCT03503149 is actively recruiting participants. Contact the research team at ghazaleh.tabatabai@med.uni-tuebingen.de for enrollment information.
Where is the NCT03503149 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT03503149 clinical trial?
NCT03503149 is sponsored by University Hospital Tuebingen. The principal investigator is Ghazaleh Tabatabai, Prof at University Hospital Tübingen. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.